Initial digest — GIPR receipt

what this node claims

Initial digest — GIPR

AlphaFold v6 prediction landed for **GIPR** (Glucose-dependent insulinotropic polypeptide receptor). UniProt accession: `P48546`. Lane: `metabolic`. Mean per-residue pLDDT: **78.47**. Tirzepatide-class dual-agonist ta...

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

78.5

466 residues / min 26.89 / max 97.44 / source alphafold db

Very high 36.1% 168 residues / >=90

Confident 38.2% 178 residues / 70-89

Low 15.7% 73 residues / 50-69

Very low 10.1% 47 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 466 of 466 residues.

residues 424-466 / mean 40.08
residues 328-352 / mean 56.95
residues 15-30 / mean 48.79
residues 354-367 / mean 60.25

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — GIPR